Jim Cramer Is Focused on These 15 Stocks This Week

4. Medtronic plc (NYSE:MDT)

Talking about Medtronic plc (NYSE:MDT), Cramer said:

“Worth watching, Medtronic reports too. I really like the new Medtronic with so many good medical devices, some of which are very successfully integrating artificial intelligence. It has been a winner.”

Medtronic (NYSE:MDT) develops and sells medical devices and therapies across various segments, including cardiovascular, neuroscience, medical-surgical, and diabetes, offering products. The company recently reported its financial results for the second quarter of fiscal year 2025, reflecting solid growth across various business segments.

The company achieved total revenue of $8.4 billion, marking an increase of 5.3% compared to the previous year. This growth was accompanied by a notable rise in profitability, with GAAP net income reaching $1.270 billion, up by 40%, and diluted earnings per share (EPS) increasing 46% to $0.99.

Medtronic’s Cardiovascular division saw substantial performance, with revenue of $3.102 billion, up 6.1% from the prior year. This segment remains a significant contributor to the company’s overall financial results. Meanwhile, the Neuroscience Portfolio posted strong results as well, generating $2.451 billion in revenue, an increase of 7.1%.

Medtronic’s (NYSE:MDT) Medical Surgical Portfolio also contributed positively, with revenue rising 1.2% to $2.128 billion. Additionally, the Diabetes segment reported a particularly strong performance, with revenue reaching $686 million, a 12.4% increase.